A global perspective in second‐line treatment patterns for patients with advanced esophageal squamous cell carcinoma
Abstract Background Esophageal cancer is a highly prevalent cancer associated with low survival, especially among those with advanced disease. Second‐line (2L) treatment patterns and related clinical outcomes of patients with advanced esophageal squamous cell carcinoma (advESCC) treated in routine c...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-05-01
|
| Series: | Thoracic Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1111/1759-7714.14334 |
| _version_ | 1811301167442952192 |
|---|---|
| author | Dena H. Jaffe Joseph Gricar Marc DeCongelio deMauri S. Mackie |
| author_facet | Dena H. Jaffe Joseph Gricar Marc DeCongelio deMauri S. Mackie |
| author_sort | Dena H. Jaffe |
| collection | DOAJ |
| description | Abstract Background Esophageal cancer is a highly prevalent cancer associated with low survival, especially among those with advanced disease. Second‐line (2L) treatment patterns and related clinical outcomes of patients with advanced esophageal squamous cell carcinoma (advESCC) treated in routine clinical care were examined globally and regionally. Methods A retrospective, noninterventional study collected physician‐provided chart data of patients aged ≥20 years receiving either 2L active systemic therapy or BSC following first‐line active therapy for advESCC from 11 countries in Asian and Western regions (September–October 2018). Bivariate analyses examined treatment and outcomes by region. Results AdvESCC patients (Asia = 192; West = 195) were examined, of which 58.1% (Asia n = 101; West n = 124) received active systemic therapy. While regional differences in tumor classification and staging at diagnosis were observed with less advanced tumors in Asia, no regional differences for these characteristics at 2L initiation were reported. Both taxane‐ and nontaxane‐based therapies were used as 2L therapy among Asian and Western patients, although more western than Asian patients received immuno‐ or targeted therapies (17.0% vs. 3.0%; p = 0.001). Alopecia (10.7%), neutropenia (9.3%), and fatigue (9.3%) were the most‐commonly reported adverse events (AEs) in both regions. Significantly higher 2L AE‐related emergency room visits (Asia = 22.5% vs. West = 8.0%; p < 0.001) and hospitalizations (Asia = 25.9 ± 31.2 vs. West = 4.7 ± 7.0, p < 0.001) were observed in Asian than in Western patients. No regional differences were reported for response to 2L treatment or the percent of patients who received third‐line treatment/died. Conclusions While regional variations were observed throughout the course of a patient's advESCC journey, disease response and treatment outcomes were similar. |
| first_indexed | 2024-04-13T07:04:05Z |
| format | Article |
| id | doaj.art-22e267d7dbc348b8959218323a02159f |
| institution | Directory Open Access Journal |
| issn | 1759-7706 1759-7714 |
| language | English |
| last_indexed | 2024-04-13T07:04:05Z |
| publishDate | 2022-05-01 |
| publisher | Wiley |
| record_format | Article |
| series | Thoracic Cancer |
| spelling | doaj.art-22e267d7dbc348b8959218323a02159f2022-12-22T02:57:02ZengWileyThoracic Cancer1759-77061759-77142022-05-011391240125710.1111/1759-7714.14334A global perspective in second‐line treatment patterns for patients with advanced esophageal squamous cell carcinomaDena H. Jaffe0Joseph Gricar1Marc DeCongelio2deMauri S. Mackie3RWE Cerner Enviza Jerusalem IsraelWWHEOR Bristol‐Myers Squibb Princeton New Jersey USAResearch and Consulting Cerner Enviza New York New York USARWE Cerner Enviza New York New York USAAbstract Background Esophageal cancer is a highly prevalent cancer associated with low survival, especially among those with advanced disease. Second‐line (2L) treatment patterns and related clinical outcomes of patients with advanced esophageal squamous cell carcinoma (advESCC) treated in routine clinical care were examined globally and regionally. Methods A retrospective, noninterventional study collected physician‐provided chart data of patients aged ≥20 years receiving either 2L active systemic therapy or BSC following first‐line active therapy for advESCC from 11 countries in Asian and Western regions (September–October 2018). Bivariate analyses examined treatment and outcomes by region. Results AdvESCC patients (Asia = 192; West = 195) were examined, of which 58.1% (Asia n = 101; West n = 124) received active systemic therapy. While regional differences in tumor classification and staging at diagnosis were observed with less advanced tumors in Asia, no regional differences for these characteristics at 2L initiation were reported. Both taxane‐ and nontaxane‐based therapies were used as 2L therapy among Asian and Western patients, although more western than Asian patients received immuno‐ or targeted therapies (17.0% vs. 3.0%; p = 0.001). Alopecia (10.7%), neutropenia (9.3%), and fatigue (9.3%) were the most‐commonly reported adverse events (AEs) in both regions. Significantly higher 2L AE‐related emergency room visits (Asia = 22.5% vs. West = 8.0%; p < 0.001) and hospitalizations (Asia = 25.9 ± 31.2 vs. West = 4.7 ± 7.0, p < 0.001) were observed in Asian than in Western patients. No regional differences were reported for response to 2L treatment or the percent of patients who received third‐line treatment/died. Conclusions While regional variations were observed throughout the course of a patient's advESCC journey, disease response and treatment outcomes were similar.https://doi.org/10.1111/1759-7714.14334advanced ESCCEsophageal cancerhealthcare resource utilizationsecond‐linetreatment patterns |
| spellingShingle | Dena H. Jaffe Joseph Gricar Marc DeCongelio deMauri S. Mackie A global perspective in second‐line treatment patterns for patients with advanced esophageal squamous cell carcinoma Thoracic Cancer advanced ESCC Esophageal cancer healthcare resource utilization second‐line treatment patterns |
| title | A global perspective in second‐line treatment patterns for patients with advanced esophageal squamous cell carcinoma |
| title_full | A global perspective in second‐line treatment patterns for patients with advanced esophageal squamous cell carcinoma |
| title_fullStr | A global perspective in second‐line treatment patterns for patients with advanced esophageal squamous cell carcinoma |
| title_full_unstemmed | A global perspective in second‐line treatment patterns for patients with advanced esophageal squamous cell carcinoma |
| title_short | A global perspective in second‐line treatment patterns for patients with advanced esophageal squamous cell carcinoma |
| title_sort | global perspective in second line treatment patterns for patients with advanced esophageal squamous cell carcinoma |
| topic | advanced ESCC Esophageal cancer healthcare resource utilization second‐line treatment patterns |
| url | https://doi.org/10.1111/1759-7714.14334 |
| work_keys_str_mv | AT denahjaffe aglobalperspectiveinsecondlinetreatmentpatternsforpatientswithadvancedesophagealsquamouscellcarcinoma AT josephgricar aglobalperspectiveinsecondlinetreatmentpatternsforpatientswithadvancedesophagealsquamouscellcarcinoma AT marcdecongelio aglobalperspectiveinsecondlinetreatmentpatternsforpatientswithadvancedesophagealsquamouscellcarcinoma AT demaurismackie aglobalperspectiveinsecondlinetreatmentpatternsforpatientswithadvancedesophagealsquamouscellcarcinoma AT denahjaffe globalperspectiveinsecondlinetreatmentpatternsforpatientswithadvancedesophagealsquamouscellcarcinoma AT josephgricar globalperspectiveinsecondlinetreatmentpatternsforpatientswithadvancedesophagealsquamouscellcarcinoma AT marcdecongelio globalperspectiveinsecondlinetreatmentpatternsforpatientswithadvancedesophagealsquamouscellcarcinoma AT demaurismackie globalperspectiveinsecondlinetreatmentpatternsforpatientswithadvancedesophagealsquamouscellcarcinoma |